RANDALL DAVIS, MD
Osteopathic Medicine at 19 St, Birmingham, AL

7317087, Jan 8, 2008

Mar 25, 2003

10/508374

Randall S. Davis - Birmingham AL, US
Max D. Cooper - Birmingham AL, US

The UAB Research Foundation - Birmingham AL

C07K 14/00

530350

The invention relates to members of the Fc receptor homolog (FcRH) subfamily, as well as fragments and variants thereof. Each FcRH is a Type I transmembrane receptor, preferably, comprises an extracellular region, a transmembrane region, and a cytoplasmic region. The cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory or activation motifs (“ITIMs” or “ITAMs). The invention provides polypeptides, nucleic acids, vectors, expression systems, and antibodies and antibody fragments related to the FcRHs as well as uses thereof. Such uses include uses in the diagnosis and treatment of a malignancy of hematopoietic cell lineage or an inflammatory or autoimmune disease in a subject and in the modulation of a humoral immune response in a subject.

8648171, Feb 11, 2014

Aug 7, 2007

11/835226

Randall S. Davis - Birmingham AL, US
Max D. Cooper - Birmingham AL, US

The UAB Research Foundation - Birmingham AL

C07K 16/00, C12P 21/08, C07K 14/00

5303871, 5303873, 5303877, 5303879, 5303881, 53038822, 5303887, 53038873, 5303888, 5303911

The invention relates to members of the Fc receptor homolog (FcRH) subfamily, as well as fragments and variants thereof. Each FcRH is a Type I transmembrane receptor, preferably, comprises an extracellular region, a transmembrane region, and a cytoplasmic region. The cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory or activation motifs (“ITIMs” or “ITAMs). The invention provides polypeptides, nucleic acids, vectors, expression systems, and antibodies and antibody fragments related to the FcRHs as well as uses thereof. Such uses include uses in the diagnosis and treatment of a malignancy of hematopoietic cell lineage or an inflammatory or autoimmune disease in a subject and in the modulation of a humoral immune response in a subject.

2008013, Jun 5, 2008

Sep 27, 2005

11/576022

Randall S. Davis - Birmingham AL, US
Max D. Cooper - Birmingham AL, US
Chuen-Miin Leu - Taipei City, TW
Goetz R. Ehrhardt - Birmingham AL, US

THE UAB RESEARCH FOUNDATION - Birmingham AL

A61K 39/395, C07K 16/18, C12N 5/06, G01N 33/564, A61P 37/00, G01N 33/574, G01N 33/567

4241381, 5303877, 5303873, 435330, 435326, 435 723, 435 721, 436507, 4241721

Provided herein are antibodies having the same epitope specificity as an antibody produced by the hybridoma cell line deposited with the American Type Culture Collection as hybridoma 4-2A6, 1-5A3, or 1-3B4. Further provided herein are methods of identifying and selecting cells that express FcRH1 or FcRH4. Methods of diagnosing and treating a subject with a malignancy of a hematopoietic cell lineage or an autoimmune disease and methods of modulating a humoral immune response in a subject are also provided herein. Further provided herein are polypeptides comprising one or more complementary determining regions of the disclosed antibodies and nucleic acids that encode the disclosed polypeptides.

2011008, Apr 14, 2011

May 13, 2010

12/779761

Randall S. Davis - Birmingham AL, US
Max D. Cooper - Birmingham AL, US
Chuen-Miin Leu - Taipai City, TW
Goetz R. A. Ehrhardt - Birmingham AL, US

THE UAB RESEARCH FOUNDATION - Birmingham AL

A61K 39/395, C07K 16/28, A61P 35/00, C12N 5/16, G01N 33/53

4241731, 5303871, 5303873, 53038815, 435326, 435 71

Provided herein are antibodies having the same epitope specificity as an antibody produced by the hybridoma cell line deposited with the American Type Culture Collection as hybridoma 4-2A6, 1-5A3, or 1-3B4. Further provided herein are methods of identifying and selecting cells that express FcRH1 or FcRH4. Methods of diagnosing and treating a subject with a malignancy of a hematopoietic cell lineage or an autoimmune disease and methods of modulating a humoral immune response in a subject are also provided herein. Further provided herein are polypeptides comprising one or more complementary determining regions of the disclosed antibodies and nucleic acids that encode the disclosed polypeptides.

2010028, Nov 11, 2010

Sep 12, 2008

12/677754

Randall S. Davis - Birmingham AL, US

THE UAB RESEARCH FOUNDATION - Birmingham AL

A61K 39/395, G01N 33/68, C07K 16/18, A61P 35/02

4241331, 435 721, 436501, 436 64, 5303871, 4241741, 5303873

Provided are methods of diagnosing in a subject a type of B-cell chronic lymphocytic leukemia (B-CLL). Also provided are antibodies, including monoclonal antibodies, that specifically bind FCRL2, FCRL3 or FCRL5 and methods of treating B-CLL using the antibodies.